{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:09Z","timestamp":1794047469091,"version":"4.8.0"},"reference-count":50,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Preclinical and clinical data demonstrate synergy between belantamab mafodotin (belamaf) and immunomodulatory drugs with limited overlapping toxicities. We investigated the safety and efficacy of belamaf with lenalidomide 25 mg on days 1-21 every 28 days and dexamethasone 40 mg weekly (belamaf-Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma. Thirty-six patients (median age, 72.5 years) were randomized to receive belamaf at three different doses (2.5, 1.9, or 1.4 mg\/kg) every 8 weeks. The dosing schedule was extended to every 12 weeks to mitigate ocular toxicity. Most common grade \u22653 adverse events were fatigue (n=21, 58.3%), rash (n=6, 16.7%), diarrhea (n=8, 22.2%) and COVID-19 (n=5, 13.9%). Grade 3-4 ocular adverse events, comprising visual acuity decline from baseline and\/or keratopathy, were reported in 39\/216 (18.1%), 33\/244 (13.5%), and 26\/207 (12.6%) ophthalmological assessments in the 2.5, 1.9, and 1.4 mg\/kg cohorts, respectively. Importantly, grade 3-4 keratopathy was identified in 9\/216 (4.2%), 1\/244 (0.4%) and 1\/207(0.5%) assessments. Most patients (32\/36, 88.9%) were treated with the extended, every-12-week schedule, during which 40, 33 and 16 doses were withheld due to ocular adverse events in the 2.5, 1.9, and 1.4 mg\/kg cohorts, respectively. Overall, the rates of very good partial response and better and complete response and better were 83.3% and 52.8%, respectively, without significant differences among cohorts. Over a median follow-up of 20.3 months no disease progression was reported; six patients discontinued treatment due to infection-related death (4 cases of COVID-19, 2 cases of pneumonia) and one patient withdrew consent. Based on the toxicity\/efficacy balance, the recommended phase II dose was 1.9 mg\/kg every 8 weeks, extended to every 12 weeks because of toxicity. In conclusion, Belamaf-Rd, with the extended schedule for belamaf, showed important clinical activity and a significant improvement of ocular adverse events with minimal impact on vision-related functioning in an elderly, non-transplant eligible population.<\/jats:p>","DOI":"10.3324\/haematol.2023.284347","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T03:26:35Z","timestamp":1707967595000},"page":"2594-2605","source":"Crossref","is-referenced-by-count":9,"title":["Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I\/II study"],"prefix":"10.3324","volume":"109","author":[{"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalini","family":"Migkou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Spiliopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis V.","family":"Kostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodanthi-Eleni","family":"Syrigou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Eleutherakis-Papaiakovou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Gkolfinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ourania E.","family":"Tsitsilonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"64652","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Moreau P, Terpos E. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021; 5(2):e528.","DOI":"10.1097\/HS9.0000000000000659"},{"key":"64653","doi-asserted-by":"crossref","unstructured":"Durie BGM, Hoering A, Sexton R. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020; 10(5):53.","DOI":"10.1038\/s41408-020-0311-8"},{"key":"64654","doi-asserted-by":"crossref","unstructured":"Mateos MV, San-Miguel J, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone (D-VMP) versus bortezomib, melphalan, and prednisone (VMP) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 Alcyone study. Blood. 2022; 140(Suppl 1):10157-10159.","DOI":"10.1182\/blood-2022-163347"},{"key":"64655","doi-asserted-by":"crossref","unstructured":"Facon T, Kumar SK, Weisel K. Daratumumab plus lenalidomide and dexamethasone in patients with transplant-ineligible newly diagnosed multiple myeloma: Maia age subgroup analysis. Blood. 2022; 140(Suppl 1):10133-10136.","DOI":"10.1182\/blood-2022-163555"},{"key":"64656","doi-asserted-by":"crossref","unstructured":"Mateos MV, Dimopoulos MA, Cavo M. Daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021; 21(11):785-798.","DOI":"10.1016\/j.clml.2021.06.005"},{"key":"64657","doi-asserted-by":"crossref","unstructured":"Facon T, Cook G, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022; 36(4):1066-1077.","DOI":"10.1038\/s41375-021-01488-8"},{"key":"64658","doi-asserted-by":"crossref","unstructured":"Korst C, van de Donk N. Should all newly diagnosed MM patients receive CD38 antibody-based treatment?. Hematology Am Soc Hematol Educ Program. 2020; 2020(1):259-263.","DOI":"10.1182\/hematology.2020000161"},{"key":"64659","doi-asserted-by":"crossref","unstructured":"Narsipur N, Bulla S, Yoo C. Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma. J Manag Care Spec Pharm. 2021; 27(12):1691-1702.","DOI":"10.18553\/jmcp.2021.27.12.1691"},{"key":"64660","doi-asserted-by":"crossref","unstructured":"Li S, Li J, Peng L. First-line daratumumab in addition to chemotherapy for newly diagnosed multiple myeloma patients who are transplant ineligible: a cost-effectiveness analysis. Clin Ther. 2021; 43(7):1253-1264.","DOI":"10.1016\/j.clinthera.2021.05.015"},{"key":"64661","doi-asserted-by":"crossref","unstructured":"Tai YT, Mayes PA, Acharya C. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-3138.","DOI":"10.1182\/blood-2013-10-535088"},{"key":"64662","doi-asserted-by":"crossref","unstructured":"Lonial S, Lee HC, Badros A. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020; 21(2):207-221.","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"64663","doi-asserted-by":"crossref","unstructured":"Trudel S, Lendvai N, Popat R. Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019; 9(4):37.","DOI":"10.1038\/s41408-019-0196-6"},{"key":"64664","doi-asserted-by":"crossref","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020; 34(4):985-1005.","DOI":"10.1038\/s41375-020-0734-z"},{"key":"64665","doi-asserted-by":"crossref","unstructured":"Zamagni E, Boccadoro M, Spencer A. MajesTEC-4 (EMN30): a phase 3 trial of teclistamab + lenalidomide versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2022; 140(Suppl 1):7289-7291.","DOI":"10.1182\/blood-2022-159756"},{"key":"64666","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Berdeja JG, Truppel-Hartmann A. KarMMa-4: idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma. J Clin Oncol. 2021; 39(15_suppl):TPS8053.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053"},{"key":"64667","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Mielnik M, Byun JM. A phase 1 study of belantamab mafodotin in combination with standard of care in newly diagnosed multiple myeloma: an interim analysis of DREAMM-9. J Clin Oncol. 2023; 41(16_suppl):8018.","DOI":"10.1200\/JCO.2023.41.16_suppl.8018"},{"key":"64668","unstructured":"European Medicines Agency. Blenrep (belantamab mafodotin). Summary of product characteristics. 2023. Publisher Full Text|"},{"key":"64669","doi-asserted-by":"crossref","unstructured":"Lonial S, Lee HC, Badros A. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021; 127(22):4198-4212.","DOI":"10.1002\/cncr.33809"},{"key":"64670","doi-asserted-by":"crossref","unstructured":"Shragai T, Magen H, Lavi N. Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: a multicentre retrospective study. Br J Haematol. 2023; 200(1):45-53.","DOI":"10.1111\/bjh.18479"},{"key":"64671","doi-asserted-by":"crossref","unstructured":"Talbot A, Bobin A, Tabone L. Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study. Haematologica. 2023; 108(10):2774-2782.","DOI":"10.1016\/S2152-2650(22)00606-1"},{"key":"64672","doi-asserted-by":"crossref","unstructured":"Vaxman I, Abeykoon J, Dispenzieri A. \u201cReal-life\u201d data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma - the Mayo Clinic experience. Blood Cancer J. 2021; 11(12):196.","DOI":"10.1038\/s41408-021-00592-3"},{"key":"64673","doi-asserted-by":"crossref","unstructured":"Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D. Real-world effectiveness and safety of belantamab mafodotin monotherapy in triple-class refractory multiple myeloma. Int J Mol Sci. 2023; 24(14):11829.","DOI":"10.3390\/ijms241411829"},{"key":"64674","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023; 10(10):e801-e812.","DOI":"10.1016\/S2352-3026(23)00243-0"},{"key":"64675","doi-asserted-by":"crossref","unstructured":"Trudel S, McCurdy A, Fu M. Belantamab mafodotin in combination with pmalidomide and dexamethasone demonstrates durable responses in triple class exposed\/ refractory multiple myeloma. Blood. 2022; 140(Suppl 1):7306-7307.","DOI":"10.1182\/blood-2022-160445"},{"key":"64676","doi-asserted-by":"crossref","unstructured":"Lasica M, Spencer A, Campbell P. P946: a phase I\/II single arm study of belantamab mafodotin, carfilzomib and dexamethasone in patients with relapsed multiple myeloma: AMARC 19-02 BELACARD study. Hemasphere. 2022; 6(Suppl):836-837.","DOI":"10.1097\/01.HS9.0000846652.51254.ac"},{"key":"64677","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15(12):e538-548.","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"64678","doi-asserted-by":"crossref","unstructured":"Palumbo A, Bringhen S, Mateos MV. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015; 125(13):2068-2074.","DOI":"10.1182\/blood-2014-12-615187"},{"key":"64679","unstructured":"Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346."},{"key":"64680","doi-asserted-by":"crossref","unstructured":"Collins J, van Noort M, Rathi C. Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma. CPT Pharmacometrics Syst Pharmacol. 2023; 12(10):1411-1424.","DOI":"10.1002\/psp4.13016"},{"key":"64681","doi-asserted-by":"crossref","unstructured":"Nooka AK, Weisel K, van de Donk NW. Belantamab mafodotin in combination with novel agents in relapsed\/ refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 2021; 17(16):1987-2003.","DOI":"10.2217\/fon-2020-1269"},{"key":"64682","doi-asserted-by":"crossref","unstructured":"Quach H, Gironella M, Lee C. Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis. J Clin Oncol. 2022; 40(16_suppl):8017.","DOI":"10.1200\/JCO.2022.40.16_suppl.8017"},{"key":"64683","doi-asserted-by":"crossref","unstructured":"Trudel S, Davis R, Lewis NM. DREAMM-8: a phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2020; 136(Suppl 1):4.","DOI":"10.1182\/blood-2020-139785"},{"key":"64684","doi-asserted-by":"crossref","unstructured":"Gonzalez-Calle V, Rodriguez Otero P, Rey-Bua B. Belantamab mafodotin in combination with Vrd for the treatment of newly diagnosed transplant eligible multiple myeloma patients: results from the phase II, open label, multicenter, GEM-BELA-Vrd trial. Blood. 2022; 140(Suppl 1):7286-7288.","DOI":"10.1182\/blood-2022-162584"},{"key":"64685","doi-asserted-by":"crossref","unstructured":"Farooq AV, Degli Esposti S, Popat R. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020; 9(4):889-911.","DOI":"10.1007\/s40123-020-00280-8"},{"key":"64686","doi-asserted-by":"crossref","unstructured":"Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000; 118(5):615-621.","DOI":"10.1001\/archopht.118.5.615"},{"key":"64687","doi-asserted-by":"crossref","unstructured":"Okumura Y, Inomata T, Iwata N. A review of dry eye questionnaires: measuring patient-reported outcomes and health-related quality of life. Diagnostics (Basel). 2020; 10(8):559.","DOI":"10.3390\/diagnostics10080559"},{"key":"64688","doi-asserted-by":"crossref","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022; 387(6):495-505.","DOI":"10.1056\/NEJMoa2203478"},{"key":"64689","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023; 29(9):2259-2267.","DOI":"10.1038\/s41591-023-02528-9"},{"key":"64690","doi-asserted-by":"crossref","unstructured":"Ludwig H, Terpos E, van de Donk N. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023; 24(6):e255-e269.","DOI":"10.1016\/S1470-2045(23)00159-6"},{"key":"64691","doi-asserted-by":"crossref","unstructured":"Vassilopoulos S, Vassilopoulos A, Kalligeros M, Shehadeh F, Mylonakis E. Cumulative incidence and relative risk of infection in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based regimens: a systematic review and meta-analysis. Open Forum Infect Dis. 2022; 9(11):ofac574.","DOI":"10.1093\/ofid\/ofac574"},{"key":"64692","doi-asserted-by":"crossref","unstructured":"Khan S, Vaisman A, Hota SS. Listeria susceptibility in patients with multiple myeloma receiving daratumumab-based therapy. JAMA Oncol. 2020; 6(2):293-294.","DOI":"10.1001\/jamaoncol.2019.5098"},{"key":"64693","doi-asserted-by":"crossref","unstructured":"Nahi H, Chrobok M, Gran C. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PLoS One. 2019; 14(2):e0211927.","DOI":"10.1371\/journal.pone.0211927"},{"key":"64694","doi-asserted-by":"crossref","unstructured":"Mazahreh F, Mazahreh L, Schinke C. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023; 7(13):3069-3074.","DOI":"10.1182\/bloodadvances.2022009435"},{"key":"64695","doi-asserted-by":"crossref","unstructured":"Reynolds G, Cliff ERS, Mohyuddin GR. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023; 7(19):5898-5903.","DOI":"10.1182\/bloodadvances.2023010539"},{"key":"64696","doi-asserted-by":"crossref","unstructured":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I. Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood. 2022; 139(9):1409-1412.","DOI":"10.1182\/blood.2021014989"},{"key":"64697","doi-asserted-by":"crossref","unstructured":"Robertson JD, Nagesh K, Jowitt SN. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer. 2000; 82(7):1261-1265.","DOI":"10.1054\/bjoc.1999.1088"},{"key":"64698","doi-asserted-by":"crossref","unstructured":"Renaud L, Schraen S, Fouquet G. Response to pneumococcal vaccination in multiple myeloma. Cancer Med. 2019; 8(8):3822-3830.","DOI":"10.1002\/cam4.2253"},{"key":"64699","doi-asserted-by":"crossref","unstructured":"Chuleerarux N, Manothummetha K, Moonla C. Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2022; 6(24):6198-6207.","DOI":"10.1182\/bloodadvances.2022008530"},{"key":"64700","doi-asserted-by":"crossref","unstructured":"Raje NS, Anaissie E, Kumar SK. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022; 9(2):e143-e161.","DOI":"10.1016\/S2352-3026(21)00283-0"},{"key":"64701","doi-asserted-by":"crossref","unstructured":"Larocca A, Bonello F, Gaidano G. Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021; 137(22):3027-3036.","DOI":"10.1182\/blood.2020009507"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284347\/76611","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284347\/77351","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11448\/76611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:44Z","timestamp":1794045944000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284347","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,15]]}}}